Screener
Halozyme Therapeutics HALO Intangibles (Net)
Intangibles (Net) at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsNet.
The source filing: Halozyme Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001159036-26-000104
| Line item | Weighted Average Useful Life (in years) | Gross Carrying Value | Accumulated Amortization | Net Carrying Value |
|---|---|---|---|---|
| Auto-injector technology platform | 7 | $402,000 | $235,735 | $166,265 |
| XYOSTED proprietary product | 10 | 136,200 | 55,908 | 80,292 |
| Hypercon developed technology platform | 15 | 230,000 | 9,498 | 220,502 |
| Customer relationships (1) | 15 | 470,000 | 19,410 | 450,590 |
| Trade name | 15 | 5,000 | 206 | 4,794 |
| Total intangible assets, net | $1,243,200 | $320,757 | $922,443 |
Item 1. Financial Statements
FAQ
- What is Halozyme Therapeutics's intangibles (net)?
- Halozyme Therapeutics (HALO) reported intangibles (net) of $922.44M in Q2 2026.
- How has Halozyme Therapeutics's intangibles (net) changed year-over-year?
- Halozyme Therapeutics's intangibles (net) increased by 190.4% year-over-year, from $317.61M to $922.44M.
- What does intangibles (net) mean?
- Identifiable intangible assets (patents, trademarks, customer relationships, technology) net of accumulated amortization — excluding goodwill.
Ask your AI about Halozyme Therapeutics's intangibles (net).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude